CCM® Therapy
Impulse Dynamics is determined to improve the lives of people with heart failure and is the developer of the innovative Optimizer® CCM® Therapy delivery system. CCM Therapy is a breakthrough heart failure treatment proven to improve quality of life for heart failure patients. CCM Therapy is specifically designed to improve systolic contraction in an effort to deliver more oxygen-rich blood to the body. CCM Therapy is a safe and effective, minimally invasive treatment option for millions of heart failure patients who otherwise have few or no effective options available to them. Optimizer® is the first and only FDA-approved device in the U.S. or elsewhere for the delivery of CCM Therapy.
Our mission at Impulse Dynamics is to exceed the expectations of patients, clinicians, and caregivers alike by developing and providing cardiac contractility modulation. The company believes in fostering innovation, transparency, and accountability in our relentless efforts to expand global access to the benefits of CCM Therapy.
AHA 2020 - Heart Failure Classification for Appropriate Device Therapy and GDMT
In this video, Dr. William Abraham discusses the overwhelming presence of Heart Failure globally. The clinical evidence points to the subjectivity of classifying heart failure functional class however this diagnosis is extremely important for treatment plans. Dr. Jagmeet Singh discusses current device options in addition to GDMT to help patients that continue to suffer from symptoms. Dr. Singh discusses the benefits of CCM® therapy for patients with NYHA Class III, EF 25 - 45%, that remain symptomatic despite being treated with Guideline Directed Medical Therapy and that are NOT indicated for Cardiac Resynchronization Therapy.
- October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
